Memantine Hydrochloride Tablet
Product Images NDC 71610-911

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71610-911). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 01)

Chemical structure diagram of memantine hydrochloride, illustrating the bicyclic amine with methyl substituents and hydrochloride component.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 02)

A line graph showing mean change from baseline in ADCS-ADL scores over 28 weeks of treatment. It compares placebo and Memantine Hydrochloride (M.HCl) groups, illustrating clinical decline and improvement trends. The x-axis represents weeks of treatment, and the y-axis shows the mean change with error bars.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 03)

A line chart showing the cumulative percentage of patients versus ADCS-ADL change from baseline, comparing Memantine Hydrochloride (M.HCl) and placebo groups. The chart includes two curves: M.HCl (open circles) and placebo (filled squares), illustrating patient response distributions over a range of ADCS-ADL changes.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 04)

A line graph depicting mean change from baseline in SIB Score over 28 weeks of treatment. It compares two groups: Placebo (square markers) and Memantine Hydrochloride (circle markers). The y-axis shows mean change with clinical improvement above zero and clinical decline below zero. The x-axis represents weeks of treatment from 0 to 28.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 05)

A cumulative percentage of patients graph showing the change from baseline in SIB scores, comparing Memantine Hydrochloride (M. HCl) to placebo. The horizontal axis represents SIB change from baseline, and the vertical axis shows cumulative percentage of patients, with Memantine Hydrochloride showing greater improvement than placebo.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 06)

A line graph depicting the mean change in ADCS-ADL score from baseline over 24 weeks of treatment. The x-axis represents weeks of treatment, and the y-axis shows the mean change (±SEM). Two lines compare Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups, with markers indicating data points and error bars. A dashed line marks clinical improvement and decline thresholds.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 07)

A cumulative percentage of patients graph showing ADCS-ADL change from baseline on the x-axis and cumulative percentage of patients on the y-axis. It compares the ADCS-ADL change for Placebo/Donepezil versus Memantine Hydrochloride (M. HCl)/Donepezil groups using two distinct data lines.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 08)

A line graph depicting mean change from baseline in SIB score over 24 weeks of treatment, comparing Placebo/Donepezil (black squares) and Memantine Hydrochloride (M.HCl)/Donepezil (open circles). The y-axis shows clinical improvement and decline, with error bars indicating SEM. The x-axis represents weeks of treatment from 0 to 24.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 09)

A cumulative percentage of patients chart showing SIB (Severe Impairment Battery) change from baseline on the x-axis and cumulative percentage on the y-axis. The chart compares two groups: Placebo/Donepezil (black squares) and Memantine Hydrochloride/Donepezil (open circles), indicating a higher cumulative percentage of patients with greater SIB change in the Memantine Hydrochloride/Donepezil group.*

FDA Label Image

Label (71619 0911 60)

Memantine Hydrochloride USP 5 mg oral tablets label displaying product strength and quantity (90 tablets). Contains storage instructions, manufacturer information (Zydus Lifesciences Ltd., India), and labeler details (Aphena Pharma Solutions - Tennessee, LLC). Includes NDC number 71610-911-60 and notes RX only status.*

FDA Label Image

Aphena (Aphena)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.